[A17-12] Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 03.07.2017
Project no.:
A17-12
Commission:
Commission awarded on 20.03.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Kidneys and urinary system
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A12-14 | Axitinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2017-09-21 A G-BA decision was published.